High frequency of BRAF V600E mutations in ameloblastoma by Kurppa, Kari J. et al.
Journal of Pathology
J Pathol 2014; 232: 492–498
Published online 31 January 2014 in Wiley Online Library
(wileyonlinelibrary.com) DOI: 10.1002/path.4317
ORIGINAL PAPER
High frequency of BRAF V600E mutations in ameloblastoma
Kari J Kurppa,1,2 Javier Cato´n,3 Peter R Morgan,3 Ari Ristima¨ki,4 Blandine Ruhin,5 Jari Kellokoski,6
Klaus Elenius1,7# and Kristiina Heikinheimo8*#
1 Department of Medical Biochemistry and Genetics and MediCity Research Laboratories, University of Turku, Finland
2 Turku Doctoral Programme of Molecular Medicine, Turku, Finland
3 Division of Clinical and Diagnostic Sciences, KCL Dental Institute, King’s College London, UK
4 Division of Pathology and Genetics, HUSLAB, Helsinki University Central Hospital, and Department of Pathology, Haartman Institute and
Genome-Scale Biology, Research Programs Unit, University of Helsinki, Finland
5 Assistance Publique-Hoˆpitaux de Paris, Maxillofacial and Stomatology Department, Pitie´-Salpeˆtrie`re Hospital, and Molecular Oral
Pathophysiology, INSERM UMRS 872, Cordeliers Biomedical Institute, Paris 7 University, France
6 Department of Oral and Maxillofacial Surgery, Institute of Dentistry, University of Eastern Finland, and Department of Oral and Maxillofacial
Diseases, Kuopio University Hospital, Finland
7 Department of Oncology, Turku University Hospital, Finland
8 Department of Oral and Maxillofacial Surgery, Institute of Dentistry, University of Turku and Turku University Hospital, Turku, and Department
of Oral Diagnostic Sciences, Institute of Dentistry, University of Eastern Finland, Kuopio, Finland
*Correspondence to: K Heikinheimo, Department of Oral and Maxillofacial Surgery, Institute of Dentistry, University of Turku, Lemminka¨isenkatu
2, FI-20520 Turku, Finland. E-mail: krihei@utu.fi
#These authors contributed equally to this study.
Abstract
Ameloblastoma is a benign but locally infiltrative odontogenic neoplasm. Although ameloblastomas rarely
metastasise, recurrences together with radical surgery often result in facial deformity and significant morbidity.
Development of non-invasive therapies has been precluded by a lack of understanding of the molecular
background of ameloblastoma pathogenesis. When addressing the role of ERBB receptors as potential new targets
for ameloblastoma, we discovered significant EGFR over-expression in clinical samples using real-time RT–PCR,
but observed variable sensitivity of novel primary ameloblastoma cells to EGFR-targeted drugs in vitro. In the
quest for mutations downstream of EGFR that could explain this apparent discrepancy, Sanger sequencing revealed
an oncogenic BRAF V600E mutation in the cell line resistant to EGFR inhibition. Further analysis of the clinical
samples by Sanger sequencing and BRAF V600E-specific immunohistochemistry demonstrated a high frequency
of BRAF V600E mutations (15 of 24 samples, 63%). These data provide novel insight into the poorly understood
molecular pathogenesis of ameloblastoma and offer a rationale to test drugs targeting EGFR or mutant BRAF as
novel therapies for ameloblastoma.
 2013 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great
Britain and Ireland.
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Introduction
Ameloblastoma is a slow-growing but locally infiltra-
tive odontogenic neoplasm of the jaws [1,2], whose
aetiology and pathogenesis are not understood. Due to
their often complex growth pattern, most ameloblas-
tomas are treated by surgical resection, often resulting
in facial deformity and significant morbidity. More
conservative approaches tend to result in recurrence
and further surgery. Targeted therapy could potentially
eliminate the need for extensive and/or repeated
surgery.
ERBB receptors are a receptor tyrosine kinase
subfamily that includes the epidermal growth factor
receptor (EGFR), ERBB2, ERBB3 and ERBB4. ERBB
receptors are indispensable for development and fre-
quently dysregulated in human malignancies [3]. EGFR
and its ligands, EGF and transforming growth factor-α
(TGFA) are expressed in the odontogenic epithelium of
normal developing teeth [4], and strong EGFR expres-
sion has also been detected in ameloblastoma [4–6].
Here, we analysed the expression of all ERBB recep-
tors in clinical ameloblastoma samples, using real-time
RT–PCR. We also studied the role of ERBB signalling
and assessed the feasibility of ERBB-targeted ther-
apeutics in novel primary ameloblastoma cell lines.
Furthermore, we report a high frequency of oncogenic
BRAF V600E mutations in clinical ameloblastoma
 2013 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
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Table 1. Clinical information and BRAF mutation status of the ameloblastoma patients; cases arranged as in Figure 1
Sample
no. Age Sex Ethnicity Location Primary/recurrent Histology Notes BRAF status
BRAF V600E
IHC
1 66 M Caucasian Right mandible Primary S/MC follicular Enucleated V600E Pos
2 70 F Asian Left mandible Primary S/MC follicular Enucleated V600E Pos
3 61 M Caucasian Right posterior
mandible
Primary S/MC plexiform Resected WT Neg
4 27 F Black-Somali Middle mandible Primary S/MC follicular Enucleated V600E Pos
5 24 F Black Right mandible Primary S/MC plexiform Enucleated V600E Pos




7 36 M Afro-Caribbean Left mandible Residual S/MC follicular Enucleated WT Neg
8 47 M Caucasian Mandible Primary S/MC follicular Resected V600E Pos
9 32 M North African Right posterior
mandible
1st recurrence S/MC plexiform Primary tumour at age
27; enucleated
WT NA
10 46 M African Middle anterior
mandible
3rd recurrence S/MC follicular Primary tumour at age
25; radical resection
V600E NA




Primary S/MC plexiform Left angle and ramus V600E Pos
12 34 F Caucasian Left posterior
mandible
1st recurrence S/MC follicular Resected V600E Pos
13 84 M Caucasian Right mandible Primary S/MC follicular Resected WT Neg
14 18 F Caucasian Left anterior
mandible
Primary S/MC follicular Enucleated V600E NA
15 16 M Caucasian Mandible Primary S/MC plexiform Enucleated V600E Pos
16 61 F NA Right mandible Primary S/MC plexiform/
follicular
Enucleated WT Neg
17 69 M Caucasian Left posterior
mandible




18 77 M Caucasian Left posterior
mandible




19 69 M Caucasian Right posterior
mandible
Primary S/MC plexiform Patient died after
operation
WT Neg
20 43 M Caucasian Right body
mandible
Primary S/MC follicular Enucleated V600E Pos
21 44 F Black-African Right posterior
mandible
Primary S/MC plexiform No recurrence after 5
years
V600E Pos
22 33 M African Middle anterior
mandible
3rd recurrence S/MC follicular Primary tumour at age
20; enucleated
V600E Pos
23 46 F Afro-Caribbean Left body mandible 1st recurrence S/MC plexiform Primary tumour at age
34; resected
V600E NA
24 31 M Black-African Left posterior
mandible





∗Decalcification of ameloblastoma tumour samples using formic acid may hinder the BRAF V600E immunohistochemistry.
S/MC, solid/multicystic; WT, wild-type; NA, data/sample not available; IHC, immunohistochemistry.
samples and demonstrate that BRAF V600E mutation
was associated with resistance to EGFR-targeted drugs
in primary ameloblastoma cells.
Materials and methods
Patients and tissue specimens
Fresh frozen tumour samples from 24 conventional
intra-osseous ameloblastomas (Table 1), eight sporadic
keratocystic odontogenic tumours (KCOT) and six
samples of normal oral mucosa (see supplementary
material, Table S1) were included in the study. Two
ameloblastoma samples were from the primary and
recurrent tumours of the same patient (samples 17 and
18; Table 1). Ethics Committee approvals (1–11 March
2007, 0/H0703/054 and CPP53-10) and the patients’
written informed consents were obtained in accordance
with the Helsinki Declaration.
Real-time RT–PCR
RNA isolation and real-time RT–PCR (TaqMan,
Applied Biosystems) analyses were carried out as
previously described [7,8]. The amount of tumour
tissue in the samples was >90%. Primer and probe
sequences have been described previously [8] or are
described in Table S2 (see supplementary material).
One ameloblastoma sample (patient sample 24) was
not included in the analysis, due to insufficient RNA
concentration.
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Establishment of primary ameloblastoma cells
and ameloblastoma fibroblasts
Fresh samples from ameloblastoma tumours (AB10,
patient 3; ABSV, patient 12; see Table 1) were
cut into small pieces (approximately 1 × 1 mm)
and placed in T25 cell culture flasks with 1 ml
CnT-24 medium (CELLnTEC), supplemented with
Pen/Strep/Amphotericin B Solution (CELLnTEC).
Outgrowing ameloblastoma cells were harvested at
confluence and maintained in the CnT-24 medium.
Primary ameloblastoma fibroblast (AF) cultures were
established from an ameloblastoma sample (tumour
not analysed in this study) as above, using Dulbecco’s
modified Eagle’s medium (DMEM; Invitrogen) sup-
plemented with 10% fetal calf serum (FCS), 50 U/ml
penicillin and 50 µg/ml streptomycin as the culture
medium.
Antibodies and inhibitors
The EGFR antibodies cetuximab and panitumumab,
as well as the ERBB2 antibody trastuzumab, were
purchased from Turku University Hospital pharmacy.
The EGFR tyrosine kinase inhibitors gefitinib and
erlotinib were purchased from Santa Cruz Biotechnol-
ogy. EGFR/ERBB4 inhibitor AG1478, PI3K inhibitor
LY294002 and MEK inhibitor PD98059 were pur-
chased from Calbiochem (Merck Millipore).
MTT cell viability assay
AB10 and ABSV cells were plated onto 96-well plates
in triplicate, at a density of 3500 cells/well, in CnT-24
Oral Epithelium Medium, with or without inhibitors.
After 72 h, the number of viable cells was estimated
using the MTT assay (CellTiter 96 non-radioactive
cell proliferation assay; Promega) according to the
manufacturer’s guidelines.
Western blotting
Cells growing on six-well plates were treated overnight
with EGFR, ERBB2, AKT or MEK inhibitors or for
10 min with EGF (R&D). Samples of cell lysates (25
µg total protein) were analysed by western blotting
with antibodies against phospho-EGFR, phospho-ERK,
phospho-AKT and ERK (cat. nos 2220, 9101, 9271 and
9102, Cell Signaling Technology) and EGFR and AKT
(sc-03 and sc-1618, Santa Cruz Biotechnology).
Targeted cDNA sequencing
Sequences coding for EGFR kinase domain and KRAS,
NRAS, HRAS or BRAF genes were PCR-amplified
and purified using NucleoSpin Gel and PCR Clean-
up kit (Macheney-Nagel). Both strands of amplified
fragments were Sanger-sequenced for recurrent muta-
tions (kinase domain for EGFR, codons 12, 13 and 61
for RAS genes, codon 600 for BRAF ). Primers used
in cDNA sequencing are described in Table S2 (see
supplementary material).
BRAF V600E immunohistochemistry
Immunohistochemical staining was performed using
BRAF V600E mutation-specific antibody VE1 (Spring
Biosciences), as previously described [9].
Statistical analyses
Real-time RT–PCR data were analysed by one-way
ANOVA, using the Games–Howell post hoc test.
MTT cell viability assays were analysed by t-test.
To analyse the relationships between BRAF mutation
status and clinical patient data, Fisher’s exact test
was used. Association of BRAF mutation status with
EGFR expression (high or low; above or below median
expression, respectively) was analysed using Fisher’s
exact test. Statistical analyses were carried out using
SPSS statistics v 20 (IBM).
Results
EGFR and ERBB4 are over-expressed
in ameloblastoma
A real-time RT–PCR analysis of 23 solid/multicystic
ameloblastomas (patient samples 1–23; Table 1) was
performed to study the expression of ERBB receptors.
Eight KCOTs and six normal oral mucosa samples were
included in the analysis as controls (see supplementary
material, Table S1). EGFR and ERBB4 were specifi-
cally over-expressed in ameloblastoma when compared
to normal samples (EGFR, p = 0.003; ERBB4 , p
= 0.01) or to KCOT (EGFR, p = 0.001; ERBB4 ,
p < 0.001) (Figure 1A, D). EGFR over-expression
is in accordance with previous studies reporting high
EGFR protein levels in ameloblastoma [4–6]. The
predominantly expressed ERBB4 receptor isoforms in
ameloblastoma were the JM-a isoforms (see supple-
mentary material, Figure S1). For ERBB2, no statisti-
cally significant differences were observed (Figure 1B).
ERBB3 was significantly more highly expressed in
KCOT than in ameloblastoma (p = 0.011) (Figure 1C).
Establishment of ameloblastoma cell lines
To address the function of ERBB receptors in
ameloblastoma, two non-immortalized primary
ameloblastoma cell lines, AB10 and ABSV, were
established from patient samples 3 and 12, respectively
(Table 1). A primary fibroblast cell line (ameloblas-
toma fibroblasts, AFs) was also established (from a
tumour not analysed in this study). AB10 and ABSV
cells were morphologically identical and formed an
epithelial-like monolayer very similar to those of two
previously published ameloblastoma cell lines [10,11],
whereas ameloblastoma fibroblasts demonstrated
a typical spindle-shaped fibroblastic morphology
(Figure 2A). The ameloblastoma cells expressed
high levels of epithelial markers KRT14 (keratin
14), KRT19 (keratin 19) and CDH1 (E-cadherin)
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Figure 1. Real-time RT–PCR analysis of ERBB receptor expression
in ameloblastoma, keratocystic odontogenic tumour (KCOT) and
normal oral mucosa. Twenty-three ameloblastomas, eight KCOTs
and six normal samples were analysed for EGFR (A), ERBB2 (B),
ERBB3 (C) or ERBB4 (D) expression.
(Figure 2B), whereas the expression of mesenchymal
markers CDH2 (N-cadherin) and VIM (vimentin) was
almost undetectable (Figure 2B). The ERBB receptor
expression pattern was similar in both ameloblas-
toma cell lines (Figure 2D) and corresponded to
that observed in the ameloblastoma tumour samples
(Figure 1). However, neither of the cell lines expressed
detectable levels of ERBB4, although ERBB4 was
expressed in the original tumour from which the AB10
cell line was established. This suggests that ERBB4




Figure 2. Characterization of established primary ameloblastoma
tumour cell lines. (A) Established AB10, ABSV and ameloblastoma
fibroblast cultures were grown on six-well plates and photographed
using ×200 magnification. (B) The cell lines were analysed for the
expression of epithelial markers KRT14 (keratin 14), KRT19 (keratin
19) and CDH1 (E-cadherin) and mesenchymal markers CDH2 (N-
cadherin) and VIM (vimentin), using real-time RT–PCR. (C) AB10
and ABSV cell lines were analysed for EGFR, ERBB2, ERBB3 and
ERBB4 expression, using real-time RT–PCR.
EGFR inhibition in ameloblastoma cells
The effect of EGFR inhibition on the proliferation of
primary ameloblastoma cells was analysed by MTT
cell viability assays. In AB10 cells, 72 h of treatment
with the EGFR antibodies cetuximab and panitumumab
already promoted a significant, dose-dependent reduc-
tion in proliferation at a concentration of 0.1 µg/ml
(p < 0.001) (Figure 3A). Consistently, the EGFR tyro-
sine kinase inhibitors (TKI) erlotinib, gefitinib and
AG1478 already significantly suppressed AB10 cell
growth at the concentration of 0.01 µM (p< 0.001, p =
0.004, and p < 0.001, respectively). However, similar
treatment with the ERBB2-antibody trastuzumab did
not demonstrate a dose-dependent effect (Figure 3A).
Treating AB10 cells with EGFR-targeted antibodies or
TKIs abolished EGFR phosphorylation and silenced
the RAS–RAF–MAPK and PI3K–AKT signalling
pathways downstream of EGFR, as seen by a reduc-
tion of ERK and AKT phosphorylation after treatment
(Figure 3B). Consistent with the proliferation assays,
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Figure 3. Effect of EGFR inhibition on ameloblastoma cells. (A) AB10 and ABSV cells were plated on 96-well plates and incubated for 72 h,
with or without the indicated concentrations of EGFR monoclonal antibodies cetuximab or panitumumab, ERBB2 monoclonal antibody
trastuzumab or EGFR tyrosine kinase inhibitors erlotinib, gefitinib or AG1478. Cell viability after incubation was estimated using the MTT
assay. *Significant differences between the proliferation of AB10 and ABSV cells (*p< 0.05, **p< 0.01, ***p< 0.001; Student’s t-test). (B)
AB10 cells were grown on six-well plates and treated overnight with cetuximab (10 µg/ml), panitumumab (10 µg/ml), trastuzumab (10
µg/ml), erlotinib (10 µM), AG1478 (10 µM), PI3-K inhibitor LY294002 (10 µM) or MEK inhibitor PD98059 (10 µM) or for 10 min with EGF
(50 ng/µl). After treatment, phosphorylation of EGFR, AKT and ERK was analysed by western blotting, using phospho-specific antibodies
(n.s., non-specific band). Total EGFR, AKT and ERK levels were determined using anti-EGFR, anti-AKT and anti-ERK antibodies. (C) The
coding region of the BRAF gene was PCR-amplified from AB10 and ABSV cell cDNA, followed by Sanger sequencing of both strands of a
320 bp amplicon flanking the V600 codon of BRAF . The arrow indicates the mutated nucleotide responsible for the V600E substitution.
ERBB2 inhibition had no major effect on the phospho-
rylation of ERK or AKT. When tested on the ABSV
cells, however, neither panitumumab nor cetuximab
had a significant effect on proliferation (Figure 3A).
The EGFR TKIs reduced proliferation of ABSV cells
by 50%, but the effect was achieved only with the
highest concentration of 10 µM. Indeed, there was a
clear, statistically significant difference in the sensitiv-
ity of AB10 and ABSV cells lines to EGFR inhibition
(Figure 3A).
BRAF mutation is associated with resistance
to EGFR-targeted drugs in primary ameloblastoma
cells
Specific genetic markers predict the response to EGFR-
targeted cancer drugs in the clinic and in vitro
[12–20]. To test whether the differences observed in
the responses to EGFR-targeted drugs in ameloblas-
toma cells were due to genetic factors, cDNA sequenc-
ing was performed to reveal mutations in the EGFR
kinase domain or in the RAS–RAF–MAPK signalling
pathway genes KRAS, NRAS, HRAS and BRAF. No
mutations were observed in the EGFR kinase domain
or in the RAS genes in either of the two cell lines.
However, the unresponsive ABSV cell line harboured a
BRAF V600E mutation (Figure 3C), caused by a point
mutation 1799T > A. These findings demonstrate that
the resistance of the ABSV cell line to EGFR-targeted
drugs was associated with an activating mutation in a
downstream signalling pathway.
BRAF mutations are frequent in ameloblastoma
Twenty-four ameloblastoma samples were analysed
for BRAF mutations by cDNA sequencing. BRAF
 2013 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2014; 232: 492–498
on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org.uk www.thejournalofpathology.com
Recurrent oncogenic mutation in ameloblastoma 497
A B
Figure 4. Analysis of BRAF V600E mutations in ameloblastoma
tumour samples. (A) The coding region of the BRAF gene was
PCR-amplified from tumour cDNA, followed by Sanger sequencing
of both strands of a 320 bp region flanking the V600 codon
of BRAF ; arrow indicates the mutated nucleotide responsible for
the V600E substitution. (B) Immunohistochemistry was performed
for tumour sections using BRAF V600E-specific monoclonal
antibody. Matching electropherograms and images from BRAF
V600E immunohistochemistry are shown for BRAF V600E-positive
(top, patient sample 20) and negative (bottom, patient sample 24)
tumours.
V600E-specific immunohistochemistry was also per-
formed for cases where appropriate tumour sections
were available. Of 24 tumours, 15 (63%) were
observed to harbour the BRAF V600E (1799T > A)
mutation (Figure 4, Table 1). In most cases, as in the
ABSV cell line (Figure 3C), the mutation appeared het-
erozygous (Figure 4A). However, as the sequencing
was performed from cDNA and the involvement of
normal tissue could not be totally excluded, gene-level
zygosity of the mutation could not be comprehensively
addressed in the tumour samples. The mutations were
found in patients with different ethnicities, including
individuals of Caucasian (n = 6), Black-African (n =
7), Afro-Caribbean (n = 1) and Asian (n = 1) ori-
gin, with no significant association to specific ethnicity.
BRAF mutation status also did not correlate with the
sex or age of the patients, tumour histology, tumour
recurrence or EGFR expression level (p > 0.1). As
expected, the original tumour from which the AB10
cell line was established (patient sample 3; Table 1)
was negative for the mutation and the tumour from
which the ABSV line was established (patient sample
12; Table 1) was positive. These findings suggest the
presence of a high-frequency oncogenic mutation in
clinical ameloblastoma.
Discussion
The pathogenesis of ameloblastoma has remained elu-
sive, despite considerable efforts to characterize the
underlying molecular mechanisms. Here, the ERBB
signalling in ameloblastoma was studied using clinical
ameloblastoma samples as well as novel ameloblas-
toma cell lines. Real-time RT–PCR analysis of ERBB
expression demonstrated a statistically significant over-
expression of EGFR and ERBB4 in ameloblastomas
(n = 23) when compared to clinical samples of KCOT
(n = 8) or to normal mucosa (n = 6). Pharmaco-
logical inhibition of EGFR suppressed the prolifera-
tion of one primary ameloblastoma cell line (AB10)
but was ineffective for the other (ABSV). In the
quest for factors underlying this difference, a BRAF
V600E mutation was found in the resistant ABSV cell
line. These observations demonstrate that, similar to
KRAS mutations in colorectal cancer [12,17,18,20],
the BRAF V600E mutation is associated with resis-
tance to EGFR-targeted drugs in ameloblastoma cells.
BRAF V600E mutations were found in 63% (15 of
24) of the ameloblastoma samples. The high incidence
of BRAF mutations represents the first indication of a
high-frequency oncogenic mutation in ameloblastoma.
Given the high response rate of BRAF V600E-positive
metastatic melanoma to mutant BRAF-targeted inhi-
bition by vemurafenib [21] or dabrafenib [22], our
observations also offer a rationale for future testing
of BRAF-targeted therapeutics for ameloblastoma.
The presence of activating BRAF mutations suggests
the involvement of a hyperactive RAS–RAF–MAPK
pathway in the pathogenesis of ameloblastomas.
The observed dependency of AB10 cells on
EGFR signalling supports this hypothesis, as the
RAS–RAF–MAPK pathway is well known to operate
downstream of EGFR [23], and as ERK phosphoryla-
tion was completely abolished in response to EGFR
inhibition in these cells. Interestingly, transgenic mice
carrying the vHa-RAS oncogene, a constitutively
active homologue of the human HRAS, develop
odontogenic tumours that closely resemble human
ameloblastoma [24,25].
Taken together, our results indicate that a hyperactive
RAS–RAF–MAPK pathway is closely associated with
ameloblastoma pathogenesis, either through EGFR-
mediated signalling or through frequent activating
mutations in the BRAF gene. Thus, our observations
offer for the first time a rationale for designing targeted
therapies in ameloblastoma.
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Figure S1. Real-time RT–PCR analysis of the expression of ERBB4 receptor isoforms in ameloblastoma, keratocystic odontogenic tumour (KCOT)
and normal oral mucosa.
Table S1. Clinical information for KCOT patients and normal sample donors.
Table S2. Primer and probe sequences used in real-time RT–PCR and targeted cDNA sequencing.
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